Onconova Therapeutics (ONTX) Receives News Impact Score of 0.10
Media headlines about Onconova Therapeutics (NASDAQ:ONTX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.7856112664514 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Onconova Therapeutics, Inc. (ONTX) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Head-To-Head Review: Fortress Biotech (FBIO) versus Onconova Therapeutics (ONTX) (americanbankingnews.com)
- Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting (finance.yahoo.com)
A number of brokerages have recently commented on ONTX. Maxim Group reissued a “buy” rating and issued a $6.00 price objective on shares of Onconova Therapeutics in a research report on Thursday, November 2nd. HC Wainwright began coverage on shares of Onconova Therapeutics in a research report on Monday, October 9th. They issued a “buy” rating and a $6.00 price objective on the stock. ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Dawson James reissued a “buy” rating on shares of Onconova Therapeutics in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Onconova Therapeutics has an average rating of “Buy” and an average price target of $7.33.
Shares of Onconova Therapeutics (NASDAQ ONTX) traded down $0.02 during mid-day trading on Tuesday, hitting $1.91. 50,001 shares of the stock were exchanged, compared to its average volume of 288,262. Onconova Therapeutics has a twelve month low of $1.46 and a twelve month high of $3.88.
Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.43. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. research analysts forecast that Onconova Therapeutics will post -3.03 EPS for the current year.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Stock Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related stocks with our FREE daily email newsletter.